Cannabis-based treatments make a breakthrough after the Food and
Drug Administration (FDA) approved the prescription cannabidiol medicine. A
drug Epidiolex is a formulation of cannabidiol, otherwise known as CBD, which
is used to treat different kinds of epilepsy.
Epidiolex helps patients with Dravet syndrome and Lennox-Gastaut
syndrome during the treatment process. FDAâ€™s Dr. Billy Dunn shares that the
approved drug to individually treat Dravet and Lennox-Gastaut patients will
provide an essential improvement in the approach of treatment and therapy for
people with the said conditions.
FDA advisers approved Epidiolex in April. However, the approval
only covers the use of the liquid drug for Lennox-Gastaut and Dravet syndrome
patients. Epidiolex, based on research, reduce seizures from epilepsy patients.
It also helps return some children to near-normal function.
Dravet syndrome, a rare genetic condition, affects infants. The
symptoms of the disease will start with fever-related seizures before
transitioning into more severe types of seizures â€” children suffering from
Dravet syndrome experience poor development in language and motor skills. They
also suffer from behavioral disorders and have difficulty relating to other
Lennox-Gastaut syndrome, meanwhile, usually affects children
starting at age 3 to 5. Most children with Lennox-Gastaut syndrome suffer from
learning problems and intellectual disability. Because of their condition,
children need help with daily activities.
In recent studies, medical marijuana has shown benefits in
combatting anxiety, counteracting nausea, and may affect symptoms of glaucoma
and sclerosis. The substance is legal in 29 U.S. States, Guam, and Puerto Rico.
Along with Epidiolex, the FDA approves other cannabis-based
products like the synthetic formulation Marinol, which could treat severe
appetite loss and nausea in diseases such as AIDS.
A Step Forward with Precautions
Despite the big step to the approval of cannabis for medical
purposes, the FDA remains insistent that the acceptance of Epidiolex is not an
approval of marijuana for medical purposes in general. FDA Commissioner Dr.
Scott Gottlieb states that cannabis-based drugs being used to treat diseases
must be proven safe and effective.
Dr. Gottlieb states that the cannabis-based product is an
essential medical advancement. However, Dr. Gottlieb also notes that the FDA
approved one specific CBD formulation for a specified use. It is different from
The FDA warns the public against falsified claims that medical
companies are using to sell cannabis-based drugs. Â Cancer cures, pain
relievers, and depression medicines are among the treatments companies use to
sell marijuana-based products. The promotion of those unproven products may
hinder patients to purchase the appropriate and approved treatment for severe
and fatal diseases.
The FDA will review legitimate applications for approval of
cannabis-based drugs. However, there needs to be scientific studies and
demonstration process to prove that the products in question are safe and
Dr. Gottlieb also adds that new therapies derived from marijuana
and its components must acquire a consistent and high quality.
Epidolex, while a formulation of CBD, does not contain the amount
of tetrahydrocannabinol, or THC, needed to provide a user in what it values for
Dr. Gottlieb reveals that the approval of Epidiolex is not a
go-signal for other marijuana-based products. Epidiolex is a purified form of
CBD. It is given to patients in a reliable dosage through a reproducible
delivery route to make sure that the users will anticipate its medical benefits
instead of its recreational use.
Despite its precautions and strict regulations, the FDA
acknowledges the effects of research and scientific studies in the medical
field, especially for CBD. With the further dedication to proving the
cannabidiolâ€™s benefits in treatment and therapy, medical marijuana enthusiasts
may cover more breakthroughs for the years to come.